JP2024511851A - 改変血漿凝固第ｖｉｉｉ因子およびその使用方法 - Google Patents

改変血漿凝固第ｖｉｉｉ因子およびその使用方法 Download PDF

Info

Publication number
JP2024511851A
JP2024511851A JP2023560378A JP2023560378A JP2024511851A JP 2024511851 A JP2024511851 A JP 2024511851A JP 2023560378 A JP2023560378 A JP 2023560378A JP 2023560378 A JP2023560378 A JP 2023560378A JP 2024511851 A JP2024511851 A JP 2024511851A
Authority
JP
Japan
Prior art keywords
mhfviii
amino acid
fviii
present application
hfviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511851A5 (https=
Inventor
ワン，チージャオ
ユ，ダオジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aavnergene Inc
Original Assignee
Aavnergene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aavnergene Inc filed Critical Aavnergene Inc
Publication of JP2024511851A publication Critical patent/JP2024511851A/ja
Publication of JP2024511851A5 publication Critical patent/JP2024511851A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023560378A 2021-03-30 2021-03-30 改変血漿凝固第ｖｉｉｉ因子およびその使用方法 Pending JP2024511851A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/024916 WO2022211791A1 (en) 2021-03-30 2021-03-30 Modified plasma clotting factor viii and method of use thereof

Publications (2)

Publication Number Publication Date
JP2024511851A true JP2024511851A (ja) 2024-03-15
JP2024511851A5 JP2024511851A5 (https=) 2024-04-12

Family

ID=75588282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560378A Pending JP2024511851A (ja) 2021-03-30 2021-03-30 改変血漿凝固第ｖｉｉｉ因子およびその使用方法

Country Status (4)

Country Link
EP (1) EP4314041A1 (https=)
JP (1) JP2024511851A (https=)
CN (1) CN117157316A (https=)
WO (1) WO2022211791A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102133A1 (en) * 2013-06-24 2016-04-14 Weidong Xiao Mutant factor viii compositions and methods
WO2019197524A1 (en) * 2018-04-12 2019-10-17 Biotest Ag De-immunized factor viii molecule and pharmaceutical compositions comprising the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
AU2003249208B2 (en) 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
SE536732C2 (sv) 2011-03-04 2014-07-01 Swemac Innovation Ab Protes för steloperation av en led
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102133A1 (en) * 2013-06-24 2016-04-14 Weidong Xiao Mutant factor viii compositions and methods
WO2019197524A1 (en) * 2018-04-12 2019-10-17 Biotest Ag De-immunized factor viii molecule and pharmaceutical compositions comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 34, no. 3, JPN6025012285, 2002, pages 233 - 238, ISSN: 0005697705 *

Also Published As

Publication number Publication date
EP4314041A1 (en) 2024-02-07
CN117157316A (zh) 2023-12-01
WO2022211791A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
EP2037892B1 (en) Modified factor viii and factor ix genes and vectors for gene therapy
CN109790528B (zh) 酸性α-葡萄糖苷酶变体及其用途
US11046750B2 (en) Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto
US20220144919A1 (en) Mutant factor viii compositions and methods
WO2016210170A9 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
US20040002159A1 (en) Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof
CA3107572A1 (en) Mini-gde for the treatment of glycogen storage disease iii
JP2023503850A5 (https=)
CN116715752A (zh) 凝血因子fviii蛋白变体、表达载体和用途
US20210093735A1 (en) Methods and compositions for treatment of hemophilia
US12583907B2 (en) Modified plasma clotting factor VIII and method of use thereof
JP2024511851A (ja) 改変血漿凝固第ｖｉｉｉ因子およびその使用方法
US20210395714A1 (en) Modified factor ix polypeptides
WO2021078834A1 (en) Chimeric acid-alpha glucosidase polypeptides and uses thereof
US20250144243A1 (en) Aav capsids for improved heart transduction and detargeting of liver
HK40064488A (en) Mutant factor viii compositions and methods
Mcintosh et al. Factor VIII sequences
HK1246657B (en) Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930